BioSpace News Archive

IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on January 4, 2021, the Company granted non-statutory stock options to purchase an aggregate of 28,000 shares of the Company’s common stock to two newly hired, non-executive employees. These grants were made pursuant to the Company’s 2019 Inducement Stock Incentive Plan, were approved by the Company’s compensation committee pursuant to a delegation by the Company’s board of d

Rising incidence of infertility is likely to boost the global assisted reproductive technology market in the years to come.

The automated external defibrillators market may invite great growth on the back of technological advancements and the rise in the prevalence of cardiovascular disorders.

The global dental endodontics market can be termed as a consolidated market with a healthy level of competition among the major players as two leading players holds more than 50% of the global market, states a new market research report by Transparency Market Research.

With increased instances of numerous diseases in all worldwide locations, pharmaceutical companies are growing efforts to discover new and effectual drugs.

The medical device testing market is expected to have steady growth during the forecast period 2020-2030.

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format

AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced that Dr. Eduardo Schiffrin, Medical Director, will participate in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Friday, January 8 from 11am Eastern Standard Time.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat CIO in H2 2021.

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, announced its calendar for the publication of financial information for 2021.